Oral DNA combination for treating chronic infection of hepatitis B virus
- Summary
- An orally applied DNA composition for improving the damaged immunity associated with chronic infection of HBV and suppressing the transgenic expression in an elongated period contains an attenuated-strain bacteria cell whose target is intestinal muccosa phagocyte for transporting the plasmid carrier which carrys one or more genes coding at least part of HBV protein or peptide, or its complementary DNA. After it comes in the infected host cell, it can clear infection and reverse the immune tolerance state of chronic HBV infection.
- Supplementary Information
- Inventor: Wenhan Wu | Guoyong Yuan | Bojian Zheng
Priority Number: CN100528238C
IPC Current: A61K004800 | A61K003929 | A61K004500 | A61P000116 | A61P003112 | C12N001551
Assignee Applicant: The University of Hong Kong
Title: Oral DNA combination for treating chronic infection of hepatitis B virus | Used for treating hepatitis B virus chronic infection of oral DNA composition
Usefulness: Oral DNA combination for treating chronic infection of hepatitis B virus | Used for treating hepatitis B virus chronic infection of oral DNA composition
Summary: The oral DNA composition is useful for inducing a cell-mediated immune response in a chronically infected HBV carrier and for suppressing transgene expression for a protracted period of time (claimed).
Novelty: New oral DNA composition comprising an attenuated strain of bacteria, useful for inducing a cell-mediated immune response in a chronically infected hepatitis B virus carrier and for suppressing transgene expression
- Industry
- Biomedical
- Sub Category
- DNA/Gene Engineering
- Country/Region
- Hong Kong
For more information, please click Here
